Who We Are

Centessa is a transformational pharmaceutical company.

At Centessa, we discover and develop medicines that are transformational for patients. We operate our clinical research with the conviction that each one of our programs has the potential to change the current treatment paradigm and establish a new standard of care. We aim to achieve this patient-centric mission with a focus on developing a portfolio of highly innovative assets, unconstrained by therapeutic area or technology.

Centessa’s core medical research operating principle is to make timely, unbiased decisions driven by data and biology. We focus on making the best decisions for each asset without constraints or bias stemming from the needs of other programs in the portfolio. We are confident this unencumbered, asset-centric philosophy has the potential to deliver significant value for all stakeholders.

Transformational Medicines


We seek to pursue the best assets in a capital efficient manner with focused development teams and data-driven decision making to rapidly progress our programs through development.


Through our approach, we strive to deliver medicines that can lead to significant impact for patients who are desperately in need of new treatments.

Transformational Medicines

Our programs span discovery-stage to late-stage development and cover a range of high-value indications in rare diseases and immuno-oncology.

Centessa’s unique culture reflects our commitment to these principles. We embrace simplicity, pragmatism, make hard decisions, work with a sense of urgency and expect extraordinary results. Centessa is a transformational pharmaceutical company.

We are leaders, innovators and entrepreneurs working together to redefine the way medicines are made.
Scroll to Top
pipeline chart header registrational white

SerpinPC is a subcutaneously administered novel inhibitor of APC being developed as a potential treatment for hemophilia, regardless of severity or inhibitor status, and may also prevent bleeding associated with other bleeding disorders. Centessa is advancing the registrational program for SerpinPC in hemophilia B, which includes a set of clinical studies with multiple components. PRESent-5, initiated in late 2022, is an observational feeder study to collect prospective observational data for minimum defined periods before switching to dosing subjects in the interventional studies. The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors). Additional information on the trials can be accessed at www.clinicaltrials.gov  (NCT05605678NCT05789524NCT05789537). SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.

Reason to Believe in Target
Human Genetics Support

~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence

Hemophilia B